Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

NCT04523402 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma Recurrent

Interventions

DRUG: Neoadjuvant chemotherapy

Sponsor

Eastern Hepatobiliary Surgery Hospital